loader image
Wednesday, June 19, 2024
78 F
McAllen
We Welcome your Press Release
- Advertisement -

DHR Health Institute of Research Launches Clinical Trial for Senseye

First-Ever Mobile Phone-Based Mental Health Diagnostic Device, Participants Needed

Translate to Spanish or other 102 languages!

Amy Ramirez, Nurse Practitioner and Clinical Researcher of the DHR Health Institute for Research and Development (left) and Vanessa Vale-Saenz, Vice President of the DHR Health Behavioral Hospital (right) look on with a prospective participant of the Senseye Clinical Study. The clinical trial evaluates the use of mobile phone-based eye-tracking software as a diagnostic tool for Post Traumatic Stress Disorder. The software tool, called Senseye, looks to revolutionize the way in which healthcare providers and patients diagnose and manage mental health conditions. Image courtesy of DHR Health
Amy Ramirez, Nurse Practitioner and Clinical Researcher of the DHR Health Institute for Research and Development (left) and Vanessa Vale-Saenz, Vice President of the DHR Health Behavioral Hospital (right) look on with a prospective participant of the Senseye Clinical Study. The clinical trial evaluates the use of mobile phone-based eye-tracking software as a diagnostic tool for Post Traumatic Stress Disorder. The software tool, called Senseye, looks to revolutionize the way in which healthcare providers and patients diagnose and manage mental health conditions. Image courtesy of DHR Health

Mega Doctor News

- Advertisement -

EDINBURG, Texas – The DHR Health Institute for Research and Development announced today its launch of a clinical trial that will evaluate the use of mobile phone-based eye-tracking software as a diagnostic tool for Post Traumatic Stress Disorder (PTSD).  The software, called Senseye, looks to revolutionize the way in which healthcare providers and patients diagnose and manage mental health conditions. PTSD affects many people due to different traumatic events in their lives. If Senseye meets FDA approval, it would be used to diagnose PTSD through eye movements, without the need to conduct extensive questioning about the patient’s traumatic experience. 

The DHR Health Institute of Research is actively seeking participants diagnosed with PTSD to join this groundbreaking trial. Participants will be paid to collaborate with a trained team, ensuring confidentiality of their information while contributing to the validation of this first-ever mental health diagnostic device for a cellphone. The trial commitment is over a three-month period. 

“This break-through innovative diagnostic tool (Senseye) will play a critical role in providing high quality care through its ability to accurately and objectively diagnose patients with Post Traumatic Stress Disorder, a psychiatric illness anticipated to be more prevalent in patients presenting to DHR Health since the hospital’s designation as a Level I Trauma Center. Rapid identification of these patients with PTSD will ultimately lead to more effective and focused treatment from both a pharmacological and non-pharmacological standpoint,” said Dr. Adrian Agapito, DHR Health Psychiatrist, Chief of Behavioral Medicine for DHR Health, and Medical Director of Outpatient Services for DHR Health. 

- Advertisement -

It is the theory of the study sponsor and device creator that the eye delivers an objective signal that can generate a valid diagnostic result as accurate as today’s gold standard psychiatric questionnaires. If so, eye signals could possibly become a replacement for surveys, providing more objective, measurable data to use in mental health diagnoses and, in the future, possibly even in the intervention and treatment stages. It is also hoped that the non-invasive, rapid biofeedback responses will lead to much faster results. In the case of this pilot study, heart rate and eye movement, including pupil dilation and frequency of eye change, are monitored via video in response to images that elicit emotional responses.

Currently, the DHR Health Institute of Research and Development is looking for PTSD patients, over the age of 18, who are willing to share information privately with a professionally-trained team. The team will privately use any volunteer’s information anonymously to test the Senseye device and gather the data needed for FDA approval. If successful, the device would be available and accessible to PTSD patients nationwide.

For those interested in participating in the Senseye clinical trial, please call the DHR Health Institute of Research and Development at (956) 362-2390.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Editorial: Support Driscoll Health Plan’s Efforts to Continue Serving South Texas

As we await the outcome of Driscoll's appeal and potential legal action, state leaders must recognize the invaluable contributions of this nonprofit health plan.

Stopping Rule Forcing Healthcare Providers to Perform “Gender Transition” Procedures

“This is yet another example of Joe Biden trying to sidestep the Constitution and use agency rulemaking to advance unpopular, unlawful, and destructive policies,” said Attorney General Paxton

New Tool for Physicians to Track Continuing Education Credits

CE Broker is used by more than 250 licensing and certification boards across the country.

Rep. Cuellar Provides Update on South Texas Air Quality

Prolonged exposure to elevated levels of PM2.5 can lead to chronic respiratory and cardiovascular diseases, reduced lung function, and can even affect cognitive functions over time.
- Advertisement -
×